Progress in dodecafluoropentane emulsion as a neuroprotective agent in a rabbit stroke model

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Neuroscience

Background:

• Dodecafluoropentane emulsion (DDFPe) consists of 250 nm nanodroplets capable of carrying substantial oxygen at body temperature.
• Its small particle size facilitates oxygen delivery to hypoxic tissues, potentially bypassing limitations of red blood cells.

Purpose of the Study:

• To evaluate Dodecafluoropentane emulsion (DDFPe) as a neuroprotectant in a rabbit model of ischemic stroke.
• To determine the dose-response relationship and pharmacokinetic profile of DDFPe following intravenous administration.

Main Methods:

• New Zealand White rabbits underwent induced cerebral embolic occlusion.
• Intravenous DDFPe was administered at varying doses (0.1, 0.3, 0.6 ml/kg) starting 60 minutes post-embolization, with repeated doses every 90 minutes.
• Infarct volumes were quantified using vital stains at 7 and 24 hours post-embolization.
• Blood pharmacokinetics of DDFP were analyzed using Gas Chromatography-Mass Spectrometry (GC-MS).

Main Results:

• DDFPe treatment significantly decreased percent infarct volume in all treated groups compared to controls (p < 0.03).
• The blood half-life of DDFP was short, averaging 1.45 ± 0.17 minutes.
• Despite a short blood half-life, a therapeutic effect exceeding 90 minutes was observed, suggesting distribution in multiple body compartments.

Conclusions:

• Intravenous DDFPe demonstrates significant neuroprotective effects by reducing ischemic stroke infarct volumes in rabbits.
• The rapid clearance of DDFPe from the blood, contrasted with its prolonged therapeutic effect, indicates a complex pharmacokinetic profile.
• Further research is warranted to define the optimal dosage and duration for DDFPe therapy and to explore its potential for clinical application in stroke treatment.